Protocol Ledger

NCT06295809 · Phase II/III · TERMINATED

A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)

Interventional Phase II/III clinical trial protocol NCT06295809 sponsored by Merck & Co. in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-04-18 Enrollment: 46 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06295809
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)46 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06295809
Protocol FieldVerified Registry Value
NCT IdentifierNCT06295809
Consolidated Lead SponsorMerck & Co.
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II/III
Overall Recruitment StatusTERMINATED
Registered Enrollment46 participants (ACTUAL)
Registered Start Date2024-04-18
WhyStopped ClassificationStrategic / Business / Sponsor Decision

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Merck & Co. across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI